TransMedics Net Income From Continuing Ops from 2010 to 2024

TMDX Stock  USD 78.58  2.54  3.34%   
TransMedics Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -37.6 M in 2024. During the period from 2010 to 2024, TransMedics Net Loss regression line of annual values had significance of  0.0002 and arithmetic mean of (28,171,930). View All Fundamentals
 
Net Loss  
First Reported
2018-03-31
Previous Quarter
12.2 M
Current Value
4.2 M
Quarterly Volatility
7.6 M
 
Covid
Check TransMedics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TransMedics' main balance sheet or income statement drivers, such as Interest Expense of 11.3 M, Selling General Administrative of 125.5 M or Research Development of 22.2 M, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 19.64. TransMedics financial statements analysis is a perfect complement when working with TransMedics Valuation or Volatility modules.
  
Check out the analysis of TransMedics Correlation against competitors.

Latest TransMedics' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of TransMedics Group over the last few years. It is TransMedics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TransMedics' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

TransMedics Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(28,171,930)
Coefficient Of Variation(26.58)
Mean Deviation6,269,916
Median(24,065,000)
Standard Deviation7,488,647
Sample Variance56.1T
Range26.7M
R-Value(0.82)
Mean Square Error19.8T
R-Squared0.67
Significance0.0002
Slope(1,372,927)
Total Sum of Squares785.1T

TransMedics Net Income From Continuing Ops History

2024-37.6 M
2023-35.8 M
2022-36.2 M
2021-44.2 M
2020-28.7 M
2019-33.5 M
2018-23.8 M

About TransMedics Financial Statements

TransMedics investors use historical fundamental indicators, such as TransMedics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TransMedics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-35.8 M-37.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TransMedics Stock Analysis

When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.